In a significant move aimed at propelling advances in spinal cord injury (SCI) research and treatment, Lineage Cell Therapeutics, Inc., a pioneer in developing innovative allogeneic cell therapies, and the Christopher & Dana Reeve Foundation, a beacon of hope for individuals living with paralysis, are poised to hold the 2nd Annual Spinal Cord Injury Investor Symposium. Scheduled for June 26 and 27, 2024, this forthcoming event underscores the collaborative spirit and unwavering commitment of both entities to forge pathways towards groundbreaking SCI solutions.

Lineage Cell Therapeutics, distinguished for its efforts in addressing critical medical needs through cell-based therapies, joins hands with the Reeve Foundation, an organization relentless in its pursuit to cure spinal cord injury. Together, they aim to catalyze the development of SCI treatments by fostering a synergistic dialogue among a diverse spectrum of stakeholders, including companies at the forefront of SCI treatment innovation, regulatory bodies, esteemed opinion leaders, individuals deeply impacted by SCI, advocacy groups, and the investment sector.

The inaugural symposium, held in June 2023, set the stage for a united front against the challenges of SCI. Building on the achievements of this initial gathering, the 2nd Annual Spinal Cord Injury Investor Symposium aspires to further amplify SCI awareness, encourage clinical trial participation through the establishment of patient-centered clinical endpoints, and importantly, attract investment to fuel the discovery of novel treatments.

Set against the backdrop of the Sanford Consortium for Regenerative Medicine in La Jolla, CA, the 2nd SCIIS is not just a meeting of minds but a testament to the collaborative effort required to navigate the complexities of SCI research and treatment. The symposium promises in-depth discussions on a wide array of critical topics, including the latest in preclinical and clinical SCI treatment strategies, the nuances of the drug development process, and the exploration of more precise SCI clinical assessment tools. Moreover, it presents an opportunity to address the intersecting vulnerabilities—be it racial, ethnic, socioeconomic, or geographic—within SCI care and outcomes.

Spinal cord injuries, which typically result from severe trauma to the spinal cord, can lead to devastating functional impairments. With an estimated 18,000 new SCI cases reported annually in the U.S. alone and the lifetime cost of care for severe injuries reaching upwards of $5 million, the urgency for effective treatments cannot be overstated.

The Sanford Consortium for Regenerative Medicine plays a crucial role in this context, acting as a nexus for scientific endeavor. By amalgamating the expertise of leading life sciences research institutions, the Consortium fosters an environment ripe for innovation in stem cell-based treatments for a host of human diseases, including SCI.

Central to the mission of the Christopher & Dana Reeve Foundation is not only to fund cutting-edge SCI research but also to enhance the quality of life for those touched by paralysis. Its National Paralysis Resource Center embodies this commitment by providing vital resources and support to individuals and families navigating the challenges of paralysis.

As Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation gear up for the 2nd Annual Spinal Cord Injury Investor Symposium, the promise of collaborative discovery shines brightly on the horizon. With a shared vision and collective effort, the path to transformative SCI treatments seems more attainable than ever before, heralding a future where the impact of spinal cord injuries can be substantially mitigated.